Working... Menu

The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion (NOBLE-CTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03392415
Recruitment Status : Recruiting
First Posted : January 8, 2018
Last Update Posted : June 28, 2018
Information provided by (Responsible Party):
Leif Thuesen, Aalborg University Hospital

Brief Summary:
Randomized registry for the study of CTO PCI as adjunction to optimal medical therapy.

Condition or disease Intervention/treatment Phase
Chronic Total Occlusion of Coronary Artery Heart Failure Angina Pectoris Procedure: CTO PCI Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2000 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Randomized registry with option of crossover after 6months
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The NOrdic-Baltic Randomized Registry Study for Long-term Clinical Evaluation of Adjunction of PCI to Optimal Medical Therapy in Chronic Total Coronary Occlusion
Actual Study Start Date : June 1, 2018
Estimated Primary Completion Date : October 2037
Estimated Study Completion Date : April 2038

Arm Intervention/treatment
Active Comparator: Initial conservative treatment
Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions
Procedure: CTO PCI
attempted percutaneous coronary intervention of the chronic total coronary occlusion

Experimental: initial interventional treatment
CTO PCI attempt as initial strategy with medical optimization simultaneously
Procedure: CTO PCI
attempted percutaneous coronary intervention of the chronic total coronary occlusion

Primary Outcome Measures :
  1. All-cause mortality [ Time Frame: a minimal follow-up of 6 months ]
    All-cause mortality after inclusion of 2000 patients

  2. Quality of life assessment [ Time Frame: 6 months. ]
    Quality of life assessment by 12-Item Short Form Survey Instrument (SF-12v2)

Secondary Outcome Measures :
  1. MR perfusion [ Time Frame: 6 months ]
    Reduction of inducible myocardial perfusion defect evaluated, improvement of left ventricular function and correlation of angina and perfusion defect

  2. Echocardiography [ Time Frame: 6 months ]
    evaluation of systolic and diastolic left ventricular function compared to index echocardiography before CTO PCI.

Other Outcome Measures:
  1. Socio-economic [ Time Frame: 1 year ]
    Socio-economic consequenses of CTO PCI. Treatment cost compared to coronary bypass surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥1 CTO lesion amenable to PCI.
  • Stable and stabilized coronary artery disease
  • Symptoms (angina pectoris or shortness of breath) and/or signs of reversible perfusion defect by SPECT, PET or MR and/or angiographic/echocardiographic indication of reversible ischemia.
  • CTO lesion in a major coronary vessel supplying a significant myocardial territory (vessel diameter usually ≥3mm).

Exclusion Criteria:

  • Expected survival <1 year.
  • Renal failure on dialysis.
  • Stable non-CTO lesions treated within one month.
  • Declined informed consent.
  • Regarding CMR: allergy to contrast medium, severe obesity, claustrophobia and certain metallic implants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03392415

Layout table for location contacts
Contact: Martin K Christensen, MD +45 9766 4454
Contact: Leif Thuesen, MD +45 9766 4465

Layout table for location information
Aalborg University Hospital Recruiting
Aalborg, Denmark, 9100
Contact: Leif Thuesen, MD    +4522328264   
Sponsors and Collaborators
Leif Thuesen
Layout table for investigator information
Study Chair: Søren Pihlkjær Hjortshøj, MD Aalborg University Hospital
  Study Documents (Full-Text)

Documents provided by Leif Thuesen, Aalborg University Hospital:

Layout table for additonal information
Responsible Party: Leif Thuesen, Senior consultant, Aalborg University Hospital Identifier: NCT03392415     History of Changes
Other Study ID Numbers: N-20170063
First Posted: January 8, 2018    Key Record Dates
Last Update Posted: June 28, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Leif Thuesen, Aalborg University Hospital:
chronic total occlusion
percutaneus coronary intervention

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Angina Pectoris
Coronary Occlusion
Heart Diseases
Cardiovascular Diseases
Myocardial Ischemia
Vascular Diseases
Chest Pain
Neurologic Manifestations
Signs and Symptoms
Coronary Disease